Kalhor recognized for his work developing technologies to aid understanding of how early-life biological signals influence ...
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United KingdomApril 30, 2026 02:30 ET | ...
UCB acquires IMIDomics’ Patient Insight Business, gaining access to one of the world’s most comprehensive multi omic datasets for immune mediated inflammatory diseasesPatient Insight Business enhances ...
National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ...
STOCKHOLM, SE / ACCESS Newswire / April 30, 2026 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO ...
Pharmaceutical Technology on MSN
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.
National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec.Award provides RIME Therapeutics with a year of laboratory ...
SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- The development of new medicines increasingly depends ...
Explore India's biopharma potential as it addresses supply chain challenges and fosters innovation in biotechnology and ...
SAN DIEGO, CA, UNITED STATES, April 30, 2026 /EINPresswire.com/ — Leveraging 35+ Years of Expertise to Guide Innovation from Development Through Global Approval Gayle Freudinger is a seasoned ...
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista ...
A new, affordable generic version of Risdiplam offers a drastic cost reduction and has been proven clinically effective, yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results